Format

Send to

Choose Destination
See comment in PubMed Commons below
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7151s-7157s.

Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities.

Author information

1
Department of Neurology and Neuro-Oncology Unit, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. ewong@bidmc.harvard.edu

Abstract

Monoclonal antibodies (mAb) may change the management of central nervous system (CNS) lymphomas. This is due to the fact that traditional chemotherapies lack specificity for B-lymphoma cells and blood-brain barrier prevents adequate chemotherapy dosing in the CNS without significant systemic side effects. But in the past 5 years, the emergence of mAbs against specific receptors on B-lymphoma cells, either as a single agent or in combination with cytotoxic chemotherapies, may offer a better therapeutic index than conventional chemotherapies. The advantages of mAbs include high affinity to targets on lymphoma cells, their lack of pharmacodynamic or pharmacokinetic interactions with other drugs, and a potential for a synergistic therapeutic response when combined with conventional chemotherapies. Our review summarizes the biological behaviors of CNS lymphomas and the challenges and opportunities in using mAbs for CNS lymphomas.

PMID:
16203815
DOI:
10.1158/1078-0432.CCR-1004-0002
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center